Higuchi CM - Search Results

1

Toxicity and immunomodulatory effects of interleukin-2 after autologous bone marrow transplantation for hematologic malignancies.

Higuchi CM, Thompson JA, Petersen FB, Buckner CD, Fefer A. Higuchi CM, et al. Blood. 1991 Jun 15;77(12):2561-8. Blood. 1991. PMID: 2043762 Free article.

2

Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial.

Benyunes MC, Higuchi C, York A, Lindgren C, Thompson JA, Buckner CD, Fefer A. Benyunes MC, et al. Bone Marrow Transplant. 1995 Aug;16(2):283-8. Bone Marrow Transplant. 1995. PMID: 7581149 Clinical Trial.

3

Interleukin-2 therapy after autologous bone marrow transplantation for hematologic malignancies.

Fefer A, Benyunes MC, Massumoto C, Higuchi C, York A, Buckner CD, Thompson JA. Fefer A, et al. Semin Oncol. 1993 Dec;20(6 Suppl 9):41-5. Semin Oncol. 1993. PMID: 8284691 Review. No abstract available.

4

Interleukin-2 +/- lymphocytes as consolidative immunotherapy after autologous bone marrow transplantation for hematologic malignancies.

Fefer A, Benyunes M, Higuchi C, York A, Massumoto C, Lindgren C, Buckner CD, Thompson JA. Fefer A, et al. Acta Haematol. 1993;89 Suppl 1:2-7. doi: 10.1159/000204577. Acta Haematol. 1993. PMID: 8475668 Clinical Trial.

5

Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies.

Higuchi CM, Thompson JA, Cox T, Lindgren CG, Buckner CD, Fefer A. Higuchi CM, et al. Cancer Res. 1989 Oct 15;49(20):5509-13. Cancer Res. 1989. PMID: 2477142

6

Induction of lymphokine-activated killer activity by interleukin 4 in human lymphocytes preactivated by interleukin 2 in vivo or in vitro.

Higuchi CM, Thompson JA, Lindgren CG, Gillis S, Widmer MB, Kern DE, Fefer A. Higuchi CM, et al. Cancer Res. 1989 Dec 1;49(23):6487-92. Cancer Res. 1989. PMID: 2479463

7

Growth and autologous tumor lysis by tumor-infiltrating lymphocytes from metastatic melanoma expanded in interleukin-2 or interleukin-2 plus interleukin-4.

Lindgren CG, Thompson JA, Higuchi CM, Fefer A. Lindgren CG, et al. Among authors: higuchi cm. J Immunother Emphasis Tumor Immunol. 1993 Nov;14(4):322-8. doi: 10.1097/00002371-199311000-00012. J Immunother Emphasis Tumor Immunol. 1993. PMID: 8280715

8

Interleukin-2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia.

Benyunes MC, Massumoto C, York A, Higuchi CM, Buckner CD, Thompson JA, Petersen FB, Fefer A. Benyunes MC, et al. Among authors: higuchi cm. Bone Marrow Transplant. 1993 Aug;12(2):159-63. Bone Marrow Transplant. 1993. PMID: 8401364 Clinical Trial.

9

Enhancement by interleukin 4 of interleukin 2- or antibody-induced proliferation of lymphocytes from interleukin 2-treated cancer patients.

Treisman J, Higuchi CM, Thompson JA, Gillis S, Lindgren CG, Kern DE, Ridell SR, Greenberg PD, Fefer A. Treisman J, et al. Among authors: higuchi cm. Cancer Res. 1990 Feb 15;50(4):1160-4. Cancer Res. 1990. PMID: 2153452

10

Individual and combinatory effects of soy isoflavones on the in vitro potentiation of lymphocyte activation.

Wang W, Higuchi CM, Zhang R. Wang W, et al. Among authors: higuchi cm. Nutr Cancer. 1997;29(1):29-34. doi: 10.1080/01635589709514598. Nutr Cancer. 1997. PMID: 9383781

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

22 results

Search Page

Filters